EVOK vs. MBIO, VRPX, GOVX, PHAS, HILS, REVB, ENSC, SNGX, ARTL, and PHIO
Should you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Mustang Bio (MBIO), Virpax Pharmaceuticals (VRPX), GeoVax Labs (GOVX), PhaseBio Pharmaceuticals (PHAS), Hillstream BioPharma (HILS), Revelation Biosciences (REVB), Ensysce Biosciences (ENSC), Soligenix (SNGX), Artelo Biosciences (ARTL), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical preparations" industry.
Mustang Bio (NASDAQ:MBIO) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Mustang Bio presently has a consensus price target of $17.25, indicating a potential upside of 5,327.94%. Given Evoke Pharma's higher possible upside, equities analysts clearly believe Mustang Bio is more favorable than Evoke Pharma.
In the previous week, Mustang Bio had 3 more articles in the media than Evoke Pharma. MarketBeat recorded 3 mentions for Mustang Bio and 0 mentions for Evoke Pharma. Mustang Bio's average media sentiment score of 0.24 beat Evoke Pharma's score of 0.00 indicating that Evoke Pharma is being referred to more favorably in the news media.
Evoke Pharma received 192 more outperform votes than Mustang Bio when rated by MarketBeat users. However, 64.12% of users gave Mustang Bio an outperform vote while only 62.61% of users gave Evoke Pharma an outperform vote.
10.0% of Mustang Bio shares are held by institutional investors. 2.1% of Mustang Bio shares are held by company insiders. Comparatively, 6.1% of Evoke Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Mustang Bio has a net margin of 0.00% compared to Mustang Bio's net margin of -150.43%. Evoke Pharma's return on equity of -433.08% beat Mustang Bio's return on equity.
Evoke Pharma has higher revenue and earnings than Mustang Bio. Evoke Pharma is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
Mustang Bio has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
Summary
Mustang Bio beats Evoke Pharma on 9 of the 16 factors compared between the two stocks.
Get Evoke Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evoke Pharma Competitors List
Related Companies and Tools
